Filing Details
- Accession Number:
- 0001127602-22-002804
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-01 17:58:09
- Reporting Period:
- 2022-01-28
- Accepted Time:
- 2022-02-01 17:58:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1492422 | Apellis Pharmaceuticals Inc. | APLS | Pharmaceutical Preparations (2834) | 271537290 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1651281 | Lukas Scheibler | C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451 | Chief Innovation Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-01-28 | 642 | $38.59 | 55,090 | No | 4 | F | Direct | |
Common Stock | Disposition | 2022-01-31 | 1,233 | $38.47 | 53,857 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | F | Direct | |
No | 4 | S | Direct |
Footnotes
- This represents shares used to cover tax withholding on a Restricted Stock Unit release.
- This is a scheduled sale from 10B5-1 trading plan.